ALDX vs LENZ
ALDX: Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on addressing regulatory feedback and securing capital for development and commercialization. LENZ: LENZ Therapeutics is a commercial-stage ophthalmic company that developed VIZZ, the first FDA-approved, once-daily aceclidine-based eye drop for the treatment of presbyopia.
Side-by-side fundamentals
| Metric | ALDX | LENZ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.70 | $5.34 | |
| Market cap as of 2026-07-23 | $106M | $167M | |
| PEG as of 2026-07-23 | n/a | -0.01 | |
| Net margin as of 2026-07-23 | n/a | -519.3% | |
| Gross margin as of 2026-07-23 | n/a | +97.8% | |
| Operating margin as of 2026-07-23 | n/a | -563.8% | |
| ROE as of 2026-07-23 | -57.3% | -37.6% | LENZ higher |
| ROA as of 2026-07-23 | -36.3% | -34.8% | LENZ higher |
| Debt / equity as of 2026-07-23 | 0.36 | 0.00 | LENZ lower |
| Beta as of 2026-07-23 | 1.20 | 2.07 | |
| 1-year return as of 2026-07-22 close | -67.5% | -84.6% | ALDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.